A phase I study assessed the safety of large multivalent immunogens (LMIs) formulated using autologous lymphoma cell membranes combined with IL-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF) in dogs with untreated B-cell lymphoma. Here, IL2 is linked to lymphoma.